ArticleWellcome open research2025
Responding to and managing antibiotic shortages: a qualitative study with experts and opinion leaders.
Article in Wellcome open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic Shortages: Pharmacists' Experiences, Perspectives, and Perceived Clinical Impacts.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: We investigated the main drivers for current shortages of licensed antibiotics, existing mitigation strategies undertaken and potential barriers in their implementation through in-depth interviews with experts operating in select regions. Methods: Purposive sampling was used to identify opinion leaders with expertise in managing antibiotic supply chains, access, and shortages between August 2023 and April 2024. Consented participants were interviewed using a semi-structured interview guide developed using the PESTELI (political, economic, sociological, ecological, technological, legal, industry) framework. Data collection and analysis were iterative and recursive, using constant comparison. Results: Participants who were interviewed (n=16) had local, national, and global roles in managing and studying access, supply, and demand chain management from Europe, South Africa, India and USA. Political engagement on antibiotic shortages is reported to facilitate effective mitigation strategies, especially in areas where there is strong evidence of government investment. Legal measures have also been used; for example, pharmacists in the UK being given rights to automatically substitute antibiotics on prescriptions and negotiating with pharmaceutical companies for greater transparency on the challenges in manufacturing. Economic incentives are currently missing and are recognised as being a driver for lack of engagement on this topic from pharmaceutical industry. Greater transparency is required from the pharmaceutical companies on the manufacturing chain issues that may lead to shortages. Technologically there is a major gap in systems to forecast and manage antibiotic shortages. Sociological elements include adopting appropriate communication to not cause panic buying and hoarding by organisations when there is an impending shortage. Legislative changes are linked to the political and economic barriers for cohesive systems to manage the antibiotic manufacture and supply chain in relation to shortages. Conclusion: Currently there are limited interventions to respond to and manage shortages. The antibiotic manufacture and supply chain is complex and under the influence of PESTELI indicators which will need to be understood and mitigated in different contexts and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.